Autopsy report · NCT00595634

INTUIT Hip Fracture Outcome Study

“Could not power primary endpoint due to lost to follow-up rate”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 10 months before it stopped.
• 92 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Smith & Nephew, Inc.

Sponsor type

Industry

Conditions

Unstable Intertrochanteric Hip Fractures

Participants

92

Sites

5

Countries

United States

Trials that died the same way

• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
  “Primary endpoint not achieved” (63% match in meaning)
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
  “Primary Endpoint not met” (60% match in meaning)
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (60% match in meaning)
• A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
  “Primary (safety) endpoint reached” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.